Clinical trials: Lung Cancer, completed
Non Small Cell Lung Cancer, KRAS Gene Mutation
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
- Trial name
- NCT03704688
- Testing
- Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Both pemetrexed and cetuximab have single agent activity in NSCLC and non-overlapping toxicity profiles. While 2-drug combination therapy has proven superior to single agent therapy in the first-line setting of NSCLC, no such…
- Trial name
- NCT00216203
- Testing
- Pemetrexed, Cetuximab
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Nasser Hanna, M.D.
Lung Cancer
Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients
This randomized controlled trial will evaluate, among 54 stage early stage lung cancer patients, whether a behavioral intervention versus an educational Control group results in improved function at 6-months.
- Trial name
- NCT02755883
- Testing
- Physical activity plus positive affect, Physical activity plus education
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Weill Medical College of Cornell University
Breast Cancer, Colon Cancer
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
The study will look at conducting a medium-intense walking program called Walk With Ease with cancer patients age 60 and above who are starting chemotherapy treatment.
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer
- Trial name
- WWE (NCT01789983)
- Testing
- Walk With Ease Program, Collect Blood, GA and Other Survey Tools
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Exemestane in Post-Menopausal Women With NSCLC
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab…
- Trial name
- NCT02666105
- Testing
- Exemestane
- Where
- 18 sites in United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lung Cancer
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal…
- Trial name
- NCT00547105
- Testing
- Erlotinib, SBRT
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
NSCLC
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
The aim of this study is to explore the Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum compare with Pemetrexed/Platinum for Advanced NSCLC.
- Trial name
- NCT01769066
- Testing
- Sequential Gefitinib With Pemetrexed/Platinum, Pemetrexed/Platinum
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Fudan University
Metastatic Non-Small Cell Lung Carcinoma
Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
This is a single center, open-label, single arm study in patients with metastatic non-small cell lung cancer (NSCLC) expressing PD-L1 after failure of platinum-based combination chemotherapy.
- Trial name
- NCT03134456
- Testing
- Pembrolizumab Injection
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
Lung Adenocarcinoma, Cancer-related Fatigue
Chaigui Jieyu Qufa Decoction for CRF in Driver Gene-negative Lung Adenocarcinoma Trial
The goal of this [clinical trial] is to [evaluate whether Chaiyu Jieyu Qufa Decoction can improve cancer-related fatigue and assess its safety] in [patients aged 18-80 years with untreated lung adenocarcinoma complicated with…
- Conditions
- Lung Adenocarcinoma, Cancer-related Fatigue, Liver Depression and Spleen Deficiency Syndrome (Traditional Chinese Medicine)
- Trial name
- CJQD-CRF (NCT07890051)
- Testing
- Chai-Gui Jieyu Qufa Granules
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoplasms, Pulmonary, Thoracic Diseases
The Need of Fiberoptic Bronchoscopy for Placing an Endobronchial Blocker
The need of fiberoptic bronchoscopy for placing an endobronchial blocker. Endobronchial blockers (EBB) have been presented effective and safe alternative for lung separation in vedio-assisted thoracoscopic (VATS) operations.
- Trial name
- NCT02133235
- Testing
- conventional, auscultation
- Where
- Taiwan
- Volunteers
- 112 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer
Coaxial Drainage Versus Standard Chest Tube After Pulmonary Lobectomy
Objectives: Chest tubes are routinely inserted after thoracic surgery procedures in different size and numbers. The aim of this study is to assess the efficacy of Smart Drain Coaxial drainage compared with two standard chest…
- Trial name
- NCT04877925
- Testing
- standard chest tubes, coaxial chest tube
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- Marco Anile
Lung Cancer
Ultrasonic Energy for Pulmonary Artery Branch Sealing During VATS Lobectomy
This research program consists of a prospective, multi-institutional Phase 2 trial and an economic cost-effectiveness analysis for the use of ACE+7 in VATS lobectomy/segmentectomy compared to traditional techniques.
- Trial name
- VATS PA-ACE (NCT02719717)
- Testing
- Harmonic Ace+7
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Lung Cancer
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: have lung cancer that could not be controlled.
- Trial name
- NCT06321510
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer…
- Conditions
- Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT01700582
- Where
- 133 sites in France
- Volunteers
- 17,664 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non-small Cell Lung Cancer
Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens
The purpose of the study is to determine if rapid on-site evaluation of EBUS-TBNA samples can increase the percentage of patients with advanced non-squamous non-small cell lung cancer in whom both pathologic subtyping and…
- Trial name
- NCT01799382
- Testing
- Rapid on-site evaluation, EBUS-TBNA
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Maggiore Bellaria Hospital, Bologna
Squamous Non-small Cell Lung Cancer
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
The purpose of the Phase 1b portion of the study is to investigate how the body tolerates necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line treatment in participants with Stage IV squamous…
- Trial name
- NCT01763788
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 20 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Bone Metastasis
Bone Pain Score Validation Initiative
Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of its validity and responsiveness.
- Trial name
- ARIE (NCT02293642)
- Where
- Germany
- Volunteers
- 370 people
- Sponsor
- iOMEDICO AG
Carcinoma, Non-Small-Cell Lung
Temsirolimus and Radiation for Non-Small Cell Lung Cancer
To determine the maximum tolerated dose of the drug temsirolimus given with radiation therapy for patients with non-small cell lung cancer.
- Trial name
- NCT00796796
- Testing
- Temsirolimus, Radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per…
- Trial name
- DUART (NCT04249362)
- Testing
- Durvalumab
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.